Literature DB >> 10708274

Antipsychotic effects and tolerability of the sigma ligand EMD 57445 (panamesine) and its metabolites in acute schizophrenia: an open clinical trial.

M J Müller1, G Gründer, H Wetzel, F Müller-Siecheneder, P Marx-Dannigkeit, O Benkert.   

Abstract

Antipsychotic efficacy and side effects of the selective sigma ligand EMD 57445 (panamesine) were investigated in 12 patients (6 males, 6 females) who met DSM-III-R criteria for schizophrenia. A 4-week open clinical study revealed only modest effects of EMD 57445 and its metabolites on positive and negative symptoms of schizophrenia. Extrapyramidal and other side effects were moderate, although a significant increase in mild dyskinetic movements was found. Five patients, four of whom were females, completed the trial. Dropouts were mainly due to treatment failure. Antipsychotic effects were significantly greater in female than male patients.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10708274     DOI： 10.1016/s0165-1781(99)00100-6

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN： 0165-1781            Impact factor:   3.222


  7 in total

1.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions?

Authors:  Marilyn A Davies; Beth Ann Compton-Toth; Sandra J Hufeisen; Herbert Y Meltzer; Bryan L Roth
Journal:  Psychopharmacology (Berl)       Date:  2004-10-13       Impact factor: 4.530

Review 2.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

Review 4.  Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Tsung-Ping Su
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

5.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

6.  The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data.

Authors:  James M Brimson; Sirikalaya Brimson; Mani Iyer Prasanth; Premrutai Thitilertdecha; Dicson Sheeja Malar; Tewin Tencomnao
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

7.  No association between the sigma receptor type 1 gene and schizophrenia: results of analysis and meta-analysis of case-control studies.

Authors:  Naohiko Uchida; Hiroshi Ujike; Kenji Nakata; Manabu Takaki; Akira Nomura; Takeshi Katsu; Yuji Tanaka; Takaki Imamura; Ayumu Sakai; Shigetoshi Kuroda
Journal:  BMC Psychiatry       Date:  2003-10-21       Impact factor: 3.630
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.